Literature DB >> 26295988

Development and characterization of antibody reagents to assess anti-PEG IgG antibodies in clinical samples.

Murli Krishna1, Holly Palme1, Jia Duo1, Zheng Lin1, Martin Corbett1, Robert Dodge1, Steven Piccoli1, Heather Myler1, Renuka Pillutla1, Binodh Desilva1.   

Abstract

BACKGROUND: Polyethylene glycol (PEG) is a polymer that can be conjugated with therapeutic proteins. Monitoring anti-PEG antibodies in human subjects may be required as part of immunogenicity assessment. The lack of well-characterized anti-PEG reagents have limited our understanding of anti-PEG humoral response.
RESULTS: Antibodies reactive to PEG were engineered with a human IgG1 Fc. Surface plasmon resonance and plate-based methods demonstrated that their binding was dependent on molecular weight (MW) of PEG. Specificity experiments using chemical analogs identified their specificity.
CONCLUSION: Affinity, specificity and MW of PEG are critical characteristics that impact interactions of anti-PEG antibodies with PEG. These attributes especially MW of PEG and the assay formats may impact the ability to detect anti-PEG antibodies.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26295988     DOI: 10.4155/bio.15.112

Source DB:  PubMed          Journal:  Bioanalysis        ISSN: 1757-6180            Impact factor:   2.681


  3 in total

1.  Development of a Generic Anti-PEG Antibody Assay Using BioScale's Acoustic Membrane MicroParticle Technology.

Authors:  Huijin Dong; Johanna R Mora; Catherine Brockus; Shannon D Chilewski; Robert Dodge; Colin Merrifield; W Matthew Dickerson; Binodh DeSilva
Journal:  AAPS J       Date:  2015-07-03       Impact factor: 4.009

Review 2.  Immunogenicity Risk Assessment for PEGylated Therapeutics.

Authors:  Johanna R Mora; Joleen T White; Stephen L DeWall
Journal:  AAPS J       Date:  2020-01-28       Impact factor: 4.009

3.  A Fit-for-Purpose Method for the Detection of Human Antibodies to Surface-Exposed Components of BMS-986263, a Lipid Nanoparticle-Based Drug Product Containing a siRNA Drug Substance.

Authors:  Uma Kavita; Wendy Miller; Qin C Ji; Renuka C Pillutla
Journal:  AAPS J       Date:  2019-07-22       Impact factor: 4.009

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.